Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after PCSK9 inhibitor availability

Journal of Clinical LipidologyBuckley LF, et al. | April 14, 2020

Advertisement

In this research, nationwide trends in Medicare Part D and Medicaid expenditures on lipid-lowering therapies from 2013 to 2017 were investigated. Between 2013 to 2017, researchers aggregated 662.2 million Medicare Part D and Medicaid prescription claims with correlated expense data from the Medicare and Medicaid Drug Spending Dashboards for nine therapeutic classes of lipid-lowering therapies. In 2013, total Medicare Part D expenditures on lipid-lowering therapies was $7.01 billion and in 2017, this was $5.07 billion. The study's findings reveal that between 2013 and 2017, overall Medicare and Medicaid expenditures on lipid-lowering therapies reduced by $2.5 billion.

Read the full article on Journal of Clinical Lipidology

Advertisement